Pliant Therapeutics (PLRX) Competitors $1.34 +0.02 (+1.13%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. AUTL, CYRX, CKPT, SNDL, TRDA, OLMA, ARCT, HRTX, SEPN, and BNTCShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Autolus Therapeutics (AUTL), Cryoport (CYRX), Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Autolus Therapeutics Cryoport Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Heron Therapeutics Septerna Benitec Biopharma Autolus Therapeutics (NASDAQ:AUTL) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Which has more volatility & risk, AUTL or PLRX? Autolus Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Which has stronger earnings and valuation, AUTL or PLRX? Pliant Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$9.01M43.42-$208.38M-$0.88-1.67Pliant Therapeutics$1.58M51.67-$161.34M-$3.61-0.37 Is AUTL or PLRX more profitable? Pliant Therapeutics' return on equity of -48.91% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Pliant Therapeutics N/A -48.91%-41.09% Do insiders and institutionals hold more shares of AUTL or PLRX? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer AUTL or PLRX? Autolus Therapeutics received 154 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. Likewise, 68.25% of users gave Autolus Therapeutics an outperform vote while only 63.87% of users gave Pliant Therapeutics an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% Pliant TherapeuticsOutperform Votes7663.87% Underperform Votes4336.13% Do analysts rate AUTL or PLRX? Autolus Therapeutics currently has a consensus price target of $9.32, indicating a potential upside of 534.01%. Pliant Therapeutics has a consensus price target of $13.31, indicating a potential upside of 900.94%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Autolus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer AUTL or PLRX? In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 3 articles in the media. Pliant Therapeutics' average media sentiment score of 1.77 beat Autolus Therapeutics' score of 0.63 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAutolus Therapeutics beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.64M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.408.9226.8019.71Price / Sales51.67252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book0.176.466.804.50Net Income-$161.34M$143.98M$3.23B$248.18M7 Day Performance-2.92%2.03%1.53%0.23%1 Month Performance-11.33%4.11%10.05%12.39%1 Year Performance-90.62%-2.87%16.75%7.07% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.3214 of 5 stars$1.35+1.1%$13.31+889.8%-90.9%$82.56M$1.58M-0.4090News CoveragePositive NewsAUTLAutolus Therapeutics3.0748 of 5 stars$1.35+2.3%$9.32+590.4%-62.0%$359.23M$10.12M-1.12330High Trading VolumeCYRXCryoport3.0027 of 5 stars$7.15+1.1%$11.00+53.8%-48.4%$358.48M$214.83M-2.121,020Positive NewsGap DownCKPTCheckpoint Therapeutics2.0523 of 5 stars$4.16-0.2%$4.33+4.2%+110.1%$348.46M$41,000.00-2.2610News CoverageSNDLSNDL3.0677 of 5 stars$1.32+2.3%$3.63+174.6%-44.5%$346.86M$927.61M-4.26580Positive NewsTRDAEntrada Therapeutics2.9486 of 5 stars$8.82+5.3%$25.67+191.0%-51.0%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2672 of 5 stars$4.76+3.5%$27.67+481.2%-46.5%$325.40MN/A-2.1770ARCTArcturus Therapeutics2.9302 of 5 stars$11.59+5.6%$59.20+410.8%-59.3%$314.33M$138.39M-5.22180Analyst UpgradeGap UpHRTXHeron Therapeutics3.8545 of 5 stars$2.05-2.8%$5.50+168.3%-45.3%$312.76M$148.52M-11.39300Positive NewsAnalyst DowngradeSEPNSepterna2.0681 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportAnalyst RevisionBNTCBenitec Biopharma2.4187 of 5 stars$13.14-3.6%$24.71+88.1%+42.3%$308.15M$80,000.00-8.7020News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AUTL Alternatives CYRX Alternatives CKPT Alternatives SNDL Alternatives TRDA Alternatives OLMA Alternatives ARCT Alternatives HRTX Alternatives SEPN Alternatives BNTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRX Stock Free PLRX Stock Alerts